Cache of 29 Million AstraZeneca Doses in Italy Raises E.U. Suspicions – The New York Times

analysts believe that some of AstraZeneca’s manufacturing difficulties are also a reflection of the company’s ambitious global distribution plans. It had intended to make as many as three billion doses this year, in part by contracting its manufacturing to plants all over the world. Other vaccine makers, by contrast, are relying on only a few facilities.

That global network of factories, analysts said, had the potential to create complications in the company’s supply chain, though it is also part of what has made the vaccine so critical to the global vaccination effort.